A practical reference on Research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-01. Anything still debated is marked as such rather than presented as settled.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
=== Miscellaneous eutherian research === Lopatin & Averianov (2026) report the discovery of a new eutherian petrosal bone from the Lower Cretaceous (Aptian-Albian) strata from the Khovoor locality (Mongolia), and interpret the two eutherian petrosal reported from the Khovoor locality to date as likely belonging to two distinct taxa, possibly Prokennalestes minor and Hovurlestes noyon. Description of the endocranial anatomy of Leptictis dakotensis and L. haydeni is published by Van Gent et al. (2026). Raynaud et al. (2026) describe fossil material of Coryphodon from the Eocene strata from the Le Quesnoy site (France), compare the diagnostic characters of C. eocaenus, C. anthracoideus and C. oweni, and interpret the latter two species as junior synonyms of C. eocaenus.
A 2021 case report documented a 72‑year‑old woman with Lewy body dementia who developed fatal neuroleptic malignant syndrome (NMS) after receiving a single 156 mg intramuscular injection of paliperidone palmitate; she remained comatose and died following a prolonged hospital course after palliative care measures were initiated. The use of high‑dose, high‑potency, or long‑acting injectable formulations of antipsychotics increases the risk of developing NMS. Multiple additional case reports of NMS linked to paliperidone palmitate have been published, including a 63-year-old man (2025) who survived after treatment, and cases in a 29-year-old woman who developed severe, treatment‑refractory NMS after two doses of paliperidone palmitate (2025) and a 24-year-old man (2025).
=== 3: Primary Active Transporters === 3.A: P-P-bond-hydrolysis-driven transporters (a.k.a. ATP-driven pumps, or transport ATPases): ATP-binding cassette transporter (ABC transporter), such as MDR, CFTR V-type ATPase; ( "V" related to vacuolar ). P-type ATPase; ( "P" related to phosphorylation), such as: Na+/K+-ATPase Plasma membrane Ca2+ ATPase Proton pump F-type ATPase; ("F" related to factor), including: mitochondrial ATP synthase, chloroplast ATP synthase1 3.B: Decarboxylation-driven transporters 3.C: Methyltransfer-driven transporters 3.D: Oxidoreduction-driven transporters 3.E: Light absorption-driven transporters, such as rhodopsin
Sources: en.wikipedia.org
The addition of S. boulardii to standard triple therapy for the eradication of Helicobacter pylori infection has been associated with a modest but statistically significant increase in eradication rates in a meta-analysis. The same analysis also reported a significant reduction in common adverse effects of eradication therapy, including diarrhea and nausea.
Crude oil varies greatly in appearance depending on its composition. It is usually black or dark brown (although it may be yellowish, reddish, or even greenish). In the reservoir it is usually found in association with natural gas (which being lighter forms a "gas cap" over the petroleum) and saline water (which being heavier than most forms of crude oil, generally sinks beneath it). Crude oil may also be found in a semi-solid form mixed with sand and water, as in the Athabasca oil sands in Canada, where it is usually referred to as crude bitumen. In Canada, bitumen is considered a sticky, black, tar-like form of crude oil which is so thick and heavy that it must be heated or diluted before it will flow. Venezuela also has large amounts of oil in the Orinoco oil sands, although the hydrocarbons trapped in them are less viscous than in Canada and are usually called extra heavy oil. Oil sands resources are called unconventional oil to distinguish them from oil which can be extracted using traditional oil well methods. Between them, Canada and Venezuela contain an estimated 3.6 trillion barrels (570×10^9 m3) of bitumen and extra heavy oil, about twice the volume of the world's reserves of conventional oil.
=== Austria === In the 2013 legislative election the Social Democratic Party of Austria and the Austrian People's Party lost 5 seats and 4 seats, respectively, but with a total of 99 seats they remained in majority. On 14 October 2013 the two parties began government formation talks with each other, which resulted in the grand coalition of the Second Faymann government that was appointed by President of Austria Heinz Fischer. On 17 May 2016, it was succeeded by the Kern government, following Faymann's resignation amidst the 2016 presidential election. The First Kurz government was formed after the 2017 legislative election. Sebastian Kurz, chairman of the centre-right Austrian People's Party, known by its initials in German as ÖVP, reached an agreement on a coalition with the far-right Freedom Party of Austria (FPÖ), setting the stage for Kurz to become chancellor of Austria—the youngest head of government in Europe—for the first time. The Ibiza affair was a political scandal in Austria involving Heinz-Christian Strache, the former vice chancellor of Austria and leader of the Freedom Party (FPÖ), and Johann Gudenus, a deputy leader of the Freedom Party. The scandal caused the collapse of the Austrian governing coalition on 18 May 2019 and the announcement of an early election.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.